2-year extension study from this trial was conducted to assess the safety and efficacy of natalizumab treatment in Japanese patients.
Methods: A total of 97 patients (43 previously on placebo; 54 previously on natalizumab) who had completed the bridging study were treated with 300 mg natalizumab every 4 weeks.
Multiple sclerosis relapses, changes in Expanded Disability Status Scale (EDSS) scores, and adverse events were assessed at regular intervals. Anti-natalizumab and anti-JC virus (JCV) antibodies were measured. 
INTRODUCTION
Natalizumab, a humanized anti-a4 integrin monoclonal antibody, has demonstrated efficacy in reducing relapse rates and disability worsening over 2 years among patients with relapsing-remitting multiple sclerosis (RRMS) in phase 3 studies that enrolled predominantly non-Asian patient populations [1, 2] . Results
from the observational open-label Safety of TYSABRI Re-dosing and Treatment (STRATA) study showed that RRMS patients from the phase 3 clinical trials experienced continued reductions in annualized relapse rate (ARR), stability of Expanded Disability Status Scale (EDSS) scores, and low rates of confirmed EDSS worsening with natalizumab treatment after 4-5 years of follow-up [3] . These results have been supported by results from studies conducted in the clinical practice setting [4] [5] [6] [7] . More recently, the safety and efficacy of natalizumab in Japanese patients with RRMS was demonstrated in a 24-week phase 2 study [8] . After 24 weeks of double-blind treatment, the adjusted ARR was significantly lower in natalizumab-than placebo-treated patients (0.53 vs. 1.73, P\0.001), and a significantly larger percentage of natalizumab-than placebo-treated patients were relapse-free (79% vs. 38%, P\0.001). From baseline to week 24, the mean EDSS score improved in the natalizumab group and worsened in the placebo group (change of -0.22 vs. 0.19, P = 0.019).
Here, we report results from the 2-year open-label extension study of patients who completed the phase 2 bridging study. The primary objective of this study was to evaluate the 2-year safety and tolerability of natalizumab in Japanese patients with RRMS. The secondary objective was to evaluate the 2-year efficacy of natalizumab in this patient population.
METHODS

Study Design and Patient Population
This study was a 2-year open-label extension study of patients who successfully completed part A or part B of the phase 2 bridging study [8] . Briefly, Japanese patients (aged 18-65 years)
were eligible for the phase 2 bridging study if, prior to enrollment, they had a diagnosis of RRMS as defined by the revised McDonald criteria [9] , C1 exacerbation within the previous year, and an EDSS score [10] between 0.0 and 6.0 (inclusive) for part A and between 0.0 and 5.5 (inclusive) for part B. The use of concomitant immunosuppressive or immunomodulatory treatment (including interferon beta and long-term systemic corticosteroids) was not permitted at any time during the bridging or extension study; however, steroids were permitted in each study to treat on-study relapses.
In part A of the open-label bridging study, 12 patients received 300 mg natalizumab administered intravenously (IV) every 4 weeks for 24 weeks to assess pharmacodynamics and pharmacokinetics. Part B was a placebo-controlled double-blind study in which 94 patients were randomized (1:1) to receive 300 mg IV natalizumab or placebo every 4 weeks for 24 weeks, and the ARR and proportion of relapse-free patients were assessed. EDSS scores and changes from baseline were analyzed, although these variables were not pre-specified endpoints. The current study focused on the longer-term follow-up of subjects enrolled in parts A and B.
To avoid potential bias, the assessment of efficacy included only the population randomized to blinded treatment in part B, while safety assessments included patients enrolled in both parts A and B.
Compliance with Ethics Guidelines
The study protocol was approved by the ethics committees at each participating site, and all patients provided written informed consent. The 
Assessment of Efficacy
For the open-label extension, clinical relapses were defined as new or recurrent neurological symptoms not associated with fever or infection and lasting for C24 h. Relapses were assessed throughout the 2 years of the extension study. EDSS scores were recorded by the examining neurologist, and because the EDSS was assessed every 12 weeks, the EDSS scores presented in this analysis were collected at week 120 of the extension study.
Assessment of Safety and Tolerability
For the open-label extension, physical examinations were performed and vital signs were measured every 4 weeks, and neurological examinations and laboratory testing were conducted every 12 weeks. A 12-lead electrocardiogram was performed at week 24.
Blood samples were taken at baseline and every 12 weeks thereafter to assess serum anti-natalizumab antibodies using a bridging enzyme-linked immunosorbent assay (ELISA) [11] . Anti-JC virus (JCV) antibody testing for progressive multifocal leukoencephalopathy (PML) risk assessment was conducted every 24 weeks. Anti-JCV antibodies were detected using the STRATIFY JCV Ò two-step ELISA (Focus Diagnostics, Cypress, CA, USA) [12, 13] .
The immunogenicity population included all patients who received C1 infusion of study treatment, had a negative baseline antibody screening result, and had C1 post-baseline antibody assessment. Patients were considered persistently positive for anti-natalizumab antibodies if they had two positive results separated by C6-12 weeks. During the 24-week bridging study, the protocol was amended to include anti-JCV antibody testing at screening and week 24. Because this testing was begun when the study was already in progress, not all patients were tested for anti-JCV antibodies. During the open-label extension study,
anti-JCV antibodies were tested at the open-label baseline (week 24 of the bridging study) and every 24 weeks thereafter.
Treatment-emergent adverse events (TEAEs) were monitored throughout the study. A TEAE was defined as any untoward medical occurrence regardless of its relationship to study medication. Severity (mild, moderate, or severe) and the possible relationship to study treatment (related or not related) were determined for each TEAE. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in death, was considered by the investigator to be life-threatening, required hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability or a congenital abnormality/birth defect, or was considered by the investigator to jeopardize the patient's well-being.
Statistical Analysis
All variables were analyzed using the intent-to-treat population, which included all patients who received C1 infusion of study treatment and had C1 post-baseline assessment of the variable of interest. In the extension study, efficacy variables (ARR, the proportion of relapse-free patients, and the change in EDSS score from baseline) were analyzed only for patients who had participated in the randomized double-blind placebo-controlled portion of the bridging study (part B). ARR was calculated as the total number of relapses experienced in a treatment group divided by the total number of days in the study multiplied by 365. Using a Poisson regression model, ARRs were adjusted for baseline relapse rate (i.e., the number of relapses in the year prior to screening for the 24-week bridging study) and reported with their 95% confidence intervals (CIs). EDSS scores and changes from baseline were summarized using descriptive statistics. Safety variables were assessed in patients enrolled in the extension study who had participated in either part A or B in the bridging study and were summarized using descriptive statistics.
RESULTS
Patient Disposition
Ninety-seven patients who completed the 24-week double-blind treatment period of the bridging study were enrolled in the open-label extension, including 43 patients who had received placebo and 54 (10 from part A and 44 from part B) who had received natalizumab ( methylprednisolone (used to treat on-study relapses; 31%) ( Table 1) .
Efficacy
Multiple sclerosis (MS) relapses and changes in disability were assessed in patients from part B of the bridging study. Relapse activity after 96 weeks in the extension study is summarized in Table 2 . The mean adjusted ARR was 0.30 (95% CI: 0.18-0.52) in patients who had previously received placebo and 0.13 (95% CI:
0.05-0.29) in patients who had previously received natalizumab (Fig. 2) . Throughout
96 weeks of open-label natalizumab treatment, the proportions of patients with known relapse status who were relapse-free were 46% (12 of 26 patients) in the previously-on-placebo group and 55% (12 of 22 patients) in the previously-on-natalizumab group. Relapse-free status was unknown for an additional 17 previously-on-placebo and 22 previously-on-natalizumab patients, which includes patients who withdrew from the study and did not experience a relapse prior to withdrawal.
The mean change in EDSS score from baseline to week 120 was -0.03 in the previously-on-placebo group and -0.18 in the previously-on-natalizumab group.
Safety and Tolerability
Most patients in both treatment groups experienced C1 TEAE, including 39 of 43 patients (91%) in the previously-on-placebo group and 53 of 54 patients (98%) in the previously-on-natalizumab group. The most frequently reported TEAEs by MedDRA System Organ Class (those occurring in[30% of patients in both treatment arms) were infections and infestations, followed by nervous system and gastrointestinal disorders in both the previously-on-placebo group and the previously-on-natalizumab group (Table 3) .
Sixteen of 43 patients (37%) in the previously-on-placebo group and 17 of 54 patients (31%) in the previously-on-natalizumab group experienced TEAEs that were considered related to study treatment (Table 4) . Time on study, n (%), months 0 to \6 0 6 (14) 9 (21) 6 to \12 0 3 (7) 4 (9) 12 to \18 1 (10) 15 (34) 2 (5) 18 to \24 1 (10) 3 (7) 6 (14) 24 to \30 (Table 5) . Three previously-on-placebo patients (7%) and four previously-on-natalizumab patients (7%) experienced treatment-related SAEs. In the previously-on-placebo group, the three patients with treatment-related SAEs had meningitis and a mycoplasma infection, a skin rash, and an ectopic pregnancy, respectively. In 
Anti-Natalizumab Antibody Status
In the immunogenicity population, two patients in the previously-on-placebo group were persistently positive for anti-natalizumab antibodies. One of these patients experienced an infusion reaction, and both patients withdrew from the study. In addition, 1 patient was transiently positive for anti-natalizumab antibodies, with a positive result at week 12 and negative results at weeks 24, 36, and 48. In the previously-on-natalizumab group, no patients who were negative for anti-natalizumab antibodies during the 24-week bridging study became persistently positive for anti-natalizumab
antibodies during the open-label extension study.
Anti-JCV Antibody Status
Overall, 69 of the 92 patients tested (75%) were anti-JCV antibody-positive at some point ARR annualized relapse rate, MS multiple sclerosis a Includes patients who withdrew from the study and did not experience a relapse prior to withdrawal b Total number of relapses during the study divided by the total number of patient-years in the study c Number of relapses for each patient divided by the number of years in the study for that patient previously-on-placebo group were anti-JCV antibody-positive at baseline and overall, respectively.
DISCUSSION
The findings of this open-label extension study of natalizumab in Japanese patients with RRMS support and extend the efficacy and safety results from the preceding two-part 24-week double-blind bridging study. During the 24 weeks in the bridging study, ARR decreased from 2.00 to 0.53 in the natalizumab group and from 1.90 to 1.73 in the placebo group [8] .
During the 2-year extension study, ARR remained lower in the previously-on-natalizumab group than in the previously-on-placebo group (0.13 vs. 0.30), and the percentage of relapse-free patients appeared higher in the previously-on-natalizumab group (2) 3 (6) General disorders and administration site conditions 6 (14) 7 (13) Pyrexia 3 (7) 3 (6) Reproductive system and breast 3 (7) 7 (13) Dysmenorrhea 0 (0) 3 (6) Respiratory, thoracic, and mediastinal 6 (14) 7 (13) Blood and lymphatic 5 (12) 4 (7) Iron deficiency anemia 3 (7) 0 (0) Hepatobiliary disorders 1 (2) 3 (6) Immune system 6 (14) 3 (6) Seasonal allergy 4 (9) 2 (4) Metabolism and nutrition disorders 0 (0) 3 (6) Renal and urinary disorders 1 (2) 3 (6)
Surgical and medical procedures 0 3 (6) Neoplasms benign, malignant, unspecified (including cysts and polyps)
(9) 2 (4)
Ear and labyrinth disorders 3 (7) 1 (2) MedDRA Medical Dictionary for Regulatory Activities, MS multiple sclerosis, SOC system organ class, TEAE treatment-emergent adverse event, WBC white blood cell a As defined by MedDRA. Each patient was counted only once within each SOC/preferred term b Includes patients from part A and part B Mycoplasma infection 2 (5) Blood alkaline phosphatase increased 1 (2) 1 (2)
Gamma-glutamyltransferase increased 0 (0) 1 (2) Liver function test abnormal 0 (0) 1 (2) Alanine aminotransferase increased 0 (0) 1 (2) Aspartate aminotransferase increased 0 (0) 1
Cholesterol increased 0 (0) 1 (2) General and administration site conditions 3 (7) 4 (7)
Injection site rash 0 (0) 1
Blood and lymphatic 2 (5) 2 (4) than in the previously-on-placebo group (55% vs. 46%). Thus, slightly better efficacy was observed over the 2 years following the conclusion of the bridging study in patients who received continuous natalizumab treatment than in patients who initiated natalizumab in this extension phase, which suggests an association between earlier initiation of natalizumab and clinical benefits, similar to results seen in non-Asian populations [3] . However, statistical analysis of this potential relationship was not conducted, as it was considered inappropriate to compare 2 non-randomized groups both receiving natalizumab treatment in the open-label extension study.
Overall, changes in EDSS scores during the extension study were small in both the previously-on-placebo and previously-on-natalizumab groups, consistent with changes observed during the double-blind study [8] . The trend of EDSS score reduction in both groups and the slightly larger reduction observed in the previously-on-natalizumab group suggest that natalizumab, on average, also prevents disability progression in Japanese patients. In terms of safety and tolerability, MS relapse and nasopharyngitis were the most frequently reported events in both groups. With MS relapse excluded from the incidence rate of TEAEs, 39 of 43 patients (91%) in the previously-on-placebo group and 52 of 54 patients (96%) in the previously-on-natalizumab group experienced a TEAE. These results were generally similar to the results that included MS relapse as a TEAE.
Although the bridging study was only 24 weeks in duration, similar results were observed: 87% of placebo patients and 72% of natalizumab patients reported C1 TEAE, with MS relapse and infections the most commonly reported TEAEs in both groups [8] . The incidence of testing persistently positive for anti-natalizumab antibodies was 2% (2 of 96 patients in the immunogenicity population) in the extension study, which is slightly lower than the 3-6% incidence that has been reported in non-Asian populations [1, 3, 11] . One of the two patients who were positive for anti-natalizumab antibodies experienced an [16] . No cases of PML natalizumab during the 24-week double-blind bridging study [8] .
CONCLUSIONS
The efficacy and safety findings from the double-blind bridging study [8] 
